Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446 · View on ClinicalTrials.gov ↗

Study Summary

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.

Interventions

  • OTHER Placebo
  • DRUG NOC-110

Study Locations (20)

California

  • So Cal Clinical Research — Huntington Beach
  • Allergy and Asthma Associates of Southern California dba Southern California Research — Laguna Niguel
  • Paradigm Clinical Research Centers, LLC - Modesto — Modesto
  • NewportNativeMD,Inc — Newport Beach
  • Center for Clinical Trials, LLC — Paramount
  • Paradigm Clinical Research Centers, LLC — Redding
  • DaVinci Research LLC. — Roseville
  • Allergy & Asthma Associates of Santa Clara Valley — San Jose
  • California Allergy & Asthma Medical Group Inc. — San Jose
  • Allergy, Asthma, and Immunology Medical Group — Ventura
  • Allergy and Asthma Clinical Research Inc — Walnut Creek

Florida

  • Innovative Research of West Florida, Inc. — Clearwater
  • Omega Research Debary, LLC — DeBary
  • Jacksonville Center for Clinical Research — Jacksonville
  • Clinical Site Partners, LLC Leesburg dba Flourish Research — Leesburg

Arizona

  • Medical Research of Arizona — Scottsdale
  • AMR Phoenix — Tempe

Alabama

  • G & L Research, LLC — Foley

Arkansas

  • Little Rock Allergy & Asthma, P.A. Clinical Research Center — Little Rock

Colorado

  • Lynn Institute of Denver — Aurora

Trial Details

FieldValue
Enrollment Target 455 participants
Start Date 2024-09-24
Est. Completion 2026-04-10
Phase Phase 2

Sponsor

Nocion Therapeutics

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06504446

The ClinicalTrials.gov registry entry for NCT06504446 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nocion Therapeutics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Refractory or Unexplained Chronic Cough appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06504446 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06504446 about?

NCT06504446 is a clinical study titled "Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough". This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.

What is the current status of trial NCT06504446?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 455 participants. The study started on 2024-09-24. Estimated completion is 2026-04-10.

What conditions does trial NCT06504446 study?

This clinical trial studies the following conditions: Refractory or Unexplained Chronic Cough. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06504446?

The interventions under investigation include: Placebo (OTHER), NOC-110 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06504446?

This trial is sponsored by Nocion Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06504446 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial